SAN FERNANDO CITY, La Union (PIA) — In celebration of Earth Day, the Provincial Government of La Union (PGLU) took a step ...

Victoria’s theatre industry came together on Monday May 5th at the Comedy Theatre to reveal the winners for the 2025 Green ...

BAMCO, Inc. is an investment adviser registered with the U.S. Securities and Exchange Commission (SEC). Baron Capital, Inc.

Jacquie Ross; Senior Vice President - Treasury, Investor Relations; Gilead Sciences Inc. Daniel O'Day; Chairman, Chief Executive Officer; Gilead Sciences Inc. Johann ...

Baron Health Care Fund retreated in the first quarter of 2025, underperforming its benchmark, the Russell 3000 Health Care ...

Millions of Filipinos around the world are Catholic, thanks to the Spanish colonizers who introduced the religion mainly as a tool for social control. But we must be careful in thinking that the ...

especially the much-anticipated potential launch of the twice-yearly PrEP drug lenacapavir, as well as the Arcellx-partnered CD19 CAR-T candidate anito-cel.

Last week, biotech bigwig Gilead Sciences, Inc. GILD reported lower-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.81 missed the Zacks Consensus Estimate by a penny.

In the pipeline, we're watching for potential approval of the expanded Trodelvy indication and anito-cel (CAR-T therapy for multiple myeloma) in 2026. We sell different types of products and ...

On a positive note, the potential launch of anito-cel in multiple myeloma and Trodelvy in first-line metastatic triple negative breast cancer in 2026 will strengthen the company’s oncology business.